background
aim
investig
profil
acut
antibodi
respons
patient
provid
propos
usag
antibodi
test
clinic
practic
method
multicent
crosssect
studi
patient
singlecent
followup
studi
patient
perform
investig
featur
acut
antibodi
respons
cohort
suspect
close
contact
enrol
evalu
potenti
antibodi
test
posit
rate
igg
reach
around
day
symptom
onset
median
day
seroconvers
lgg
igm
day
symptom
onset
seroconvers
igm
occur
time
earlier
later
igg
igg
level
patient
enter
platform
within
day
seroconvers
criteria
igg
seroconvers
increas
igg
titer
sequenti
sampl
togeth
diagnos
patient
antibodi
test
aid
confirm
patient
suspect
fail
confirm
rtpcr
patient
close
contact
neg
rtpcr
igm
igg
detect
simultan
earli
phase
infect
serolog
diagnosi
criterion
seroconvers
increas
igg
titer
suitabl
major
patient
serolog
test
help
diagnosi
infect
suspect
close
contact
rapid
spread
coronaviru
diseas
worldwid
rais
concern
around
world
outbreak
first
start
wuhan
china
dramat
increas
daili
confirm
global
case
world
health
organ
declar
global
pandem
march
human
immun
respons
novel
pathogen
innat
adapt
arm
one
aspect
adapt
immun
humor
respons
featur
product
antibodi
recogn
specif
determin
antigen
call
epitop
antibodi
produc
protect
host
futur
infect
pathogen
studi
sever
acut
respiratori
syndrom
sar
middl
east
respiratori
syndrom
mer
show
antibodi
detect
patient
week
ill
onset
antibodi
persist
least
year
moreov
profil
antibodi
respons
might
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
correl
sever
diseas
outcom
mer
current
antibodi
detect
broadli
develop
antibodi
respons
remain
nearli
unknown
studi
depict
profil
acut
antibodi
respons
crosssect
analysi
patient
followup
studi
patient
also
demonstr
clinic
applic
antibodi
test
facilit
diagnosi
suspect
asymptomat
close
contact
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
total
patient
crosssect
studi
enrol
design
hospit
chongq
provincelevel
municip
adjac
hubei
startpoint
center
outbreak
china
three
hospit
chongq
three
gorg
central
hospit
tgh
yongchuan
hospit
affili
chongq
medic
univers
cqmu
ych
public
health
center
chongq
phcc
assign
chongq
municip
peopl
govern
admit
patient
design
area
indic
measur
level
igg
igm
serum
sampl
collect
patient
serum
sampl
inactiv
min
store
test
igg
igm
antibodi
plasma
sampl
test
use
magnet
chemiluminesc
enzym
immunoassay
mclia
kit
suppli
bioscienc
chongq
co
ltd
china
cfda
approv
accord
manufactur
instruct
mclia
igg
igm
detect
develop
base
doubleantibodi
sandwich
immunoassay
recombin
antigen
contain
nucleoprotein
peptid
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
spike
protein
conjug
fluorescein
isothiocyan
fitc
immobil
antifitc
antibodi
conjug
magnet
particl
alkalin
phosphatas
conjug
human
iggigm
antibodi
use
detect
antibodi
test
conduct
autom
magnet
chemiluminesc
analyz
axce
bioscienc
china
accord
manufactur
instruct
test
perform
strict
biosaf
condit
antibodi
level
express
chemiluminesc
signal
compar
cutoff
valu
sco
continu
variabl
express
median
interquartil
rang
iqr
compar
mannwhitney
u
test
categor
variabl
express
number
compar
test
fisher
exact
test
p
valu
less
consid
statist
signific
statist
analys
perform
use
r
softwar
version
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
case
patient
admit
design
hospit
enrol
crosssect
studi
median
age
enrol
patient
year
iqr
year
male
patient
histori
exposur
transmiss
sourc
patient
clear
record
symptom
onset
case
classifi
sever
critic
ill
condit
accord
guidelin
tabl
laboratori
paramet
patient
white
blood
cell
neutrophil
ddimer
hypersensit
troponin
procalcitonin
crp
creactiv
protein
lactat
dehydrogenas
alanin
aminotransferas
aspart
aminotransferas
higher
severecrit
patient
mild
patient
higher
level
lymphocyt
count
consist
recent
report
tabl
antibodi
detect
rate
base
number
day
onset
symptom
determin
summar
figur
sever
patient
nd
week
symptom
onset
sampl
sever
patient
rd
week
sampl
shown
fig
igg
igm
titer
sever
group
higher
nonsever
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
group
although
signific
statist
differ
observ
igg
level
week
group
investig
longitudin
profil
igg
igm
confirm
patient
crosssect
studi
follow
total
sequenti
serum
sampl
collect
test
parallel
igg
igm
patient
overal
seroconvers
rate
followup
period
two
patient
old
girl
mother
maintain
igg
igmneg
statu
hospit
indic
undergo
serolog
convers
observ
period
unfortun
two
patient
lost
followup
delay
seroconvers
exclud
serolog
cours
could
follow
patient
initi
seroneg
underw
seroconvers
observ
igg
seroconvers
patient
igm
seroconvers
patient
seroconvers
patient
patient
achiev
seroconvers
igg
igm
within
day
symptom
onset
median
day
seroconvers
lgg
igm
day
symptom
onset
fig
three
type
seroconvers
observ
synchron
seroconvers
igg
igm
case
igm
seroconvert
earlier
igg
case
igm
seroconvert
later
igg
case
longitudin
chang
antibodi
repres
patient
three
type
shown
fig
fig
base
find
recommend
either
igm
igg
seroconvers
use
confirm
criterion
recent
infect
tri
identifi
factor
associ
differ
seroconvers
type
found
associ
type
age
gender
hospit
time
data
shown
analyz
dynam
chang
igg
level
acut
respons
normal
time
last
neg
test
point
patient
underw
igg
seroconvers
hospit
shown
fig
igg
level
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
patient
reach
platform
day
first
posit
point
seroconvers
time
howev
igg
level
platform
differ
patient
vari
larg
igm
titer
also
show
similar
profil
dynam
chang
fig
recommend
seroconvers
increas
igg
titer
acut
ideal
first
week
ill
convalesc
serum
sampl
use
confirm
merscov
infect
thu
analyz
criterion
also
suitabl
diagnosi
patient
sampl
first
week
ill
shown
fig
patient
igg
neg
first
week
seroconvert
afterward
observ
period
eleven
patient
igg
posit
first
sampl
eventu
achiev
increas
igg
titer
point
later
howev
patient
fit
none
criteria
among
case
seroconvert
hospit
five
seem
rise
phase
igg
might
achiev
increas
futur
howev
patient
seem
enter
plateau
igg
titer
first
sampl
fig
lower
panel
unlik
igg
titer
would
increas
sometim
near
futur
overal
patient
fit
serolog
criteria
patient
alreadi
enter
platform
igg
titer
time
first
sampl
even
though
day
ill
onset
patient
achiev
seroconvers
discharg
achiev
consecut
rtpcr
data
indic
criterion
increas
igg
titer
might
stringent
confirm
minor
patient
evalu
potenti
serolog
test
diagnosi
suspect
admit
wanzhou
peopl
hospit
chongq
china
respiratori
symptom
abnorm
pulmonari
imag
neg
rtpcr
least
sequenti
test
enrol
four
patient
show
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
posit
igg
igm
first
sampl
fig
patient
show
increas
igg
latter
time
point
interestingli
rtpcr
test
patient
sampl
becam
posit
one
day
two
sampl
confirm
infect
increas
titer
igm
observ
sequenti
sampl
patient
patient
posit
igg
igm
patient
high
igg
igm
titer
higher
respect
cutoff
valu
time
point
although
latter
patient
show
seroconvers
chang
igg
titer
sequenti
sampl
still
support
diagnosi
next
use
serolog
test
cluster
close
contact
identifi
chongq
cdc
coupl
travel
back
wuhan
citi
confirm
infect
feb
deem
st
gener
patient
network
case
cohort
close
contact
either
directli
indirectli
coupl
jan
feb
total
case
confirm
rtpcr
jan
feb
case
report
symptom
case
symptom
neg
rtpcr
test
march
serum
sampl
collect
case
antibodi
test
rtpcr
confirm
case
posit
igg
orand
igm
strikingli
case
exclud
previous
neg
nucleic
acid
result
also
show
posit
result
igg
orand
igm
indic
close
contact
miss
nucleic
acid
test
addit
cohort
asymptomat
infect
featur
antibodi
respons
give
us
hint
applic
serolog
test
diagnosi
firstli
almost
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
confirm
patient
achiev
igg
igm
seroconvers
within
day
symptom
onset
evidenc
crosssect
analysi
followup
studi
find
indic
infect
rule
antibodi
still
undetect
day
symptom
onset
day
exposur
day
plu
median
incub
mother
daughter
achiev
seroconvers
either
igg
igm
hospit
emphas
necess
combin
antibodi
rtpcr
test
secondli
gener
rule
chronolog
order
igm
igg
seroconvers
specif
patient
resembl
condit
sar
mer
support
detect
igg
igm
simultan
rather
singl
antibodi
alon
thirdli
confirm
criteria
serolog
test
mer
recommend
appli
major
patient
patient
diagnos
criteria
seroconvers
increas
igg
titer
acut
ideal
first
week
ill
convalesc
serum
sampl
lead
caus
miss
patient
criteria
earli
seroconvers
within
day
even
day
symptom
onset
igg
patient
fig
middl
panel
find
highlight
import
collect
first
sampl
earli
possibl
hand
argu
patient
miss
ideal
sampl
window
second
serolog
test
sever
day
exampl
day
later
confirm
first
posit
result
would
suffici
confirm
diagnosi
symptom
chest
imag
evid
simultan
asymptomat
infect
pose
special
challeng
prevent
sinc
symptom
usual
use
import
indic
asymptomat
individu
infect
becom
transmiss
sourc
contain
quarantin
survey
cohort
close
contact
identifi
patient
occult
infect
miss
symptom
screen
nucleic
acid
test
ad
identifi
rtpcr
percentag
asymptomat
infect
high
cohort
thu
necessari
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
identifi
isol
close
contact
even
show
symptom
neg
rtpcr
result
limit
survey
one
serum
sampl
case
obtain
better
confirm
test
result
second
sampl
possibl
summari
depict
rel
complet
prospect
acut
antibodi
respons
patient
believ
antibodi
test
would
great
help
diagnosi
epidem
survey
infect
acknowledg
thank
chengyong
yang
law
yuen
kwan
ju
cao
critic
review
manuscript
acut
ideal
first
week
ill
convalesc
serum
sampl
recommend
confirm
criteria
test
whether
criteria
suitabl
among
patient
diagnos
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
criteria
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
